Candoral 2% w/w (Oral Gel)

Title and Categories

• Candoral Oral Gel
• Medicine
• Aural Anti-fungal Preparations

Description

• For the treatment of oral and gastrointestinal candidiasis
• For eradication of fungal colonization in the mouth and gastrointestinal tract
• For the treatment of super infections due to gram-positive bacteria
• Indicated in dermatomycoses such as Tinea pedis (Athlete's foot), Tinea corporis (Tinea circinata), Tinea manuum, etc.
• Rapid alleviating effect on pruritus
• Low oral bioavailability (25-30%)
• Systemically absorbed after administration as the oral gel
• Plasma protein binding (88.2%) to serum albumin and red blood cells (10.6%)
• Metabolized mostly after absorption
• Less than 1% excreted unchanged in the urine
• Terminal plasma half-life: 20-25 hours
• Suitable for infants, adults, and children
• Dosage based on age and conditions
• Recommended application frequency - 2 to 4 times a day
• Apply missed dose as soon as remembered
• Relief of symptoms within 2 to 3 days
• Lesions usually disappear after 2 to 5 weeks
• Prolonged treatment for 10 days to prevent relapse
• Interactions with Terfenadine, Astemizole, Cisapride, Phenytoin, and Cyclosporine
• Known contraindication in patients with hypersensitivity to the active ingredient
• Possible side effects: nausea, vomiting, diarrhea, allergic reactions
• No information on safety during pregnancy
• Excretion in human milk
• Caution in concomitant use with anticoagulants and phenytoin
• Overdose effects: vomiting, diarrhea
• Symptomatic and supportive treatment for overdosage
• Therapeutic class: Aural Anti-fungal Preparations
• Storage conditions: dry place, away from light and heat, keep out of reach of children

Dimensions

• N/A

Color Options

• N/A

Functions

• Antifungal activity against dermatophytes and yeasts
• Antibacterial activity against certain gram-positive bacilli and cocci
• Inhibition of demethylation step in ergosterol biosynthesis
• Disruption of fungal cell membrane leading to cell death

Materials

• Miconazole

Technical Specifications

• Oral bioavailability: 25-30%
• Plasma protein binding: 88.2%
• Absorbed portion largely metabolized
• Terminal plasma half-life: 20-25 hours

Design Elements

• Cream and gel formulations
• Measuring spoon for dosage

Usability Features

• Suitable for infants, children, and adults
• Recommended application frequency: 2 to 4 times a day
• Contraindicated in patients with known hypersensitivity to the active ingredient
• Caution required in concomitant use with anticoagulants and phenytoin
• Symptomatic and supportive treatment for overdose effects

Related Brands

• A-Migel 2% w/w (Oral Gel) - acme-laboratories-ltd